Abstract: The present invention relates to a stabilized solution comprising a hydrophobic protein, a method for the production thereof, and the stabilizing solution as a pharmaceutical, and the use thereof.

Abstract: The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu(5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) is exchanged with hydrophilic amino acid with a hydroxy group, specially serine, tyrosine or threonine, resulting in enhanced hydrophilic property of the protein surface.

Abstract: A dental drill includes a shaft and a head extending from an end of the shaft. The head includes at least one cutting edge and defines a length of greater than about 2.5 mm.

Abstract: The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu (5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) are exchanged with hydrophilic amino acid with a hydroxy group, specially serine, tyrosine or threonine, resulting in enhanced hydrophilic property of the protein surface.

Abstract: The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu(5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) is exchanged with hydrophilic amino acid with a hydroxy group, specially serine, tyrosine or threonine, resulting in enhanced hydrophilic property of the protein surface.

Abstract: The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu (5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) are exchanged with hydrophilic amino acid with a hydroxy group, specially serine, tyrosine or threonine, resulting in enhanced hydrophilic property of the protein surface.

Abstract: The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu(5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) is exchanged with hydrophilic amino acid with a hydroxy group, specially serine, tyrosine or threonine, resulting in enhanced hydrophilic property of the protein surface.

Abstract: The invention relates to a root canal instrument set comprising at least two root canal instruments, each root canal instrument being provided with a collar having a shaft end at one end and a working part including at least one cutting edge on the other end, the working part being shaped conically or crowned, wherein the cone angle of the working parts decrease from the preceding root canal instrument to the subsequent root canal instrument and the working part of the respectively preceding root canal instrument has a larger diameter than the working part of the respectively subsequent root canal instrument. Alternatively, the radii of the crowned working parts may increase from the preceding root canal instrument to the subsequent root canal instrument, and the working part of the preceding root canal instrument may have a larger diameter than the working part of the subsequent root canal instrument.

Abstract: The invention provides new variants of recombinant human interferon-.gamma. (rhIFN-.gamma.), vectors and host cells for their production, and therapeutic methods employing them. The variants are characterized by the substitution of one or more pairs of amino acids selected from Glu.sup.8 -Ser.sup.70, Ala.sup.18 -His.sup.112, Lys.sup.81 Leu.sup.121, and Gln.sup.49 -Leu.sup.96 by pairs of Cys residues, and optionally by the deletion of from one to ten amino acid residues from C-terminus of the native IFN-.gamma. sequence. The variants of the invention exhibit greater thermal stability and no loss of biological activity as compared to native-sequence rhIFN-.gamma..

Abstract: The invention relates to a method of manufacturing soluble recombinant proteins from bacteria, in which the plasmid contains the entire gene behind a promoter, this plasmid being expressed and the protein obtained being isolated and purified, in which the cell culture is raised to an OD 600 nm of 0.4 to 0.6; the cell culture is cooled over a period of 15 to 40 minutes to 20.degree. to 26.degree. C.; synthesis is induced by addition of 10 to 55 .mu.M of an inductor; and the induction phase is carried out at a temperature of 20.degree. to 26.degree. C. over a period of 3.5 to 6.5 hours.